Zhejiang Ausun Pharmaceutical Hits Day High with Strong 5.17% Gain

Zhejiang Ausun Pharmaceutical Co., Ltd. has experienced a notable increase of 5.17% on July 1, 2026, reaching an intraday high of CNY 8.16. This performance stands in contrast to the China Shanghai Composite, which recorded a modest gain of 0.44% on the same day. Despite today's uptick, the stock has faced challenges over the longer term, with a year-to-date decline of 17.94% and a significant drop of 76.74% over the past five years. The company's market capitalization is currently CNY 7,564 million, placing it within the mid-cap category of the pharmaceuticals and biotechnology industry. Key financial metrics reveal a mixed picture. The company's net sales for the latest quarter fell by 16.2%, while net profit for the half-year decreased by 23.85%. The return on equity stands at 4.73%, and the price-to-earnings ratio is notably high at 68.00, indicating a potentially expensive valuation relative to its earnings. Overall, while today's performance marks a positive moment for Zhejiang Ausun Pharmaceutical, the broader trends suggest ongoing challenges in its financial health.